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of Atrial Fibrillation?
The Hanging CHAD*
Ganesh Venkataraman, MD,
S. Adam Strickberger, MD
Washington, DC
Atrial fibrillation (AF) is the most common arrhythmia. It
is associated with a decreased quality of life, increased
hospitalizations, and a 2-fold increased risk of death. Per-
haps most importantly, the risk of a thromboembolic (TE)
event in patients with AF is increased 5-fold (1–3).
See page 2380
Multiple schema have been proposed to risk stratify
patients with AF for TE events. A simple risk assessment
scheme is the CHADS2 score (4), which evolved from the
troke Prevention in AF (SPAF) investigators criteria, and
s the primary basis for guiding antithrombotic therapy in
he 2006 American College of Cardiology/American Heart
ssociation (ACC/AHA) AF guidelines (2). More re-
ently, the CHA2DS2-VASc score was described (5). This
scoring system provides an increased emphasis on age 75
years and includes the additional risk factors of vascular
disease and female gender. The CHA2DS2-VASc score
mproves the predictive value for TE events in patients with
F (5,6). Both the CHADS2 and CHA2DS2-VASc scores
ere validated as predictors of TE events in patients with
F who were treated pharmacologically for rate and/or
hythm control. Importantly, and perhaps under-recognized,
hese studies demonstrate that the CHA2DS2-VASc score
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who have an increased risk of a TE event. That is,
CHA2DS2-VASc can identify the low-risk CHADS2 pa-
ient who is actually high risk for a TE event (5,6).
Catheter ablation is a standard treatment for patients
ith drug-refractory, symptomatic AF (2). Although the
odalities and approaches to catheter ablation of AF differ
etween centers, left atrial (LA) ablation with pulmonary
ein isolation is generally a cornerstone to this therapy.
he success rate of catheter ablation varies according to the
attern and duration of AF, the LA size, and LA substrate,
nd is approximately 70% (7). The major complication rate
ssociated with catheter ablation of AF is 3% to 5%, and is
enerally related to vascular access, although there is a small
isk of a TE event and death (7,8). TE events immediately
fter catheter ablation of AF are thought to be related to
hrombus formation on the trans-septal sheaths and cathe-
ers, or to char and thrombus formation at the ablation sites.
E events remote from the ablation procedure may be
ue to decreases in LA transport after catheter ablation of
F or to the intrinsic risk of TE events in patients with AF (9).
There have been several attempts to quantify and predict
E events and death rates in patients undergoing catheter
blation of AF. Oral et al. (10) studied 755 consecutive
atients undergoing catheter ablation of AF. All patients
ere placed on oral anticoagulation for 3 months after the
rocedure. A TE event occurred in 1.1% of patients, with
he majority of events occurring within the first two weeks.
worldwide survey of 20,825 catheter ablation procedures
or AF reported a TE event rate of 1.0% and a death rate of
.15% (7). In a recent study, 232 consecutive patients
nderwent brain magnetic resonance imaging after catheter
blation of AF. The symptomatic TE rate was 0.4%, and
he rate of silent TE events was 14% (11). These studies
ere unable to demonstrate clinical predictors of TE events
r death in patients undergoing catheter ablation of AF. In
ddition, the findings of a transesophageal echocardiogram
TEE), with the exception of a LA thrombus, do not
redict the patient at risk for a TE event after catheter
blation of AF (12).
In this issue of the Journal, Chao et al. (13) provide some
ata that help predict who is at risk for a TE event after
atheter ablation of AF. The authors evaluate the usefulness
f the CHADS2 and CHA2DS2-VASc scores to predict the
risk of TE events and death in patients undergoing catheter
ablation of AF. A total of 565 patients, of whom 440 had
paroxysmal AF, were enrolled in the study and followed for
a mean of 39.2 months. Before catheter ablation of AF, oral
anticoagulation therapy was based on the patient’s
CHADS2 score. A TEE was performed on all patients prior
o catheter ablation of AF in order to exclude the presence
f a LA thrombus. Catheter ablation of AF was performed
n a standard fashion with 2 circumferential sets of lesions
round the right and left pulmonary vein (PV) ostia with
onfirmation of PV isolation, using either a conventional
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tion sets in the LA and coronary sinus were performed
based on the persistence or inducibility of AF after PV
isolation. After catheter ablation of AF, warfarin was
administered for at least 3 months to those patients who
were receiving it before ablation. The decision to discon-
tinue warfarin after ablation was individualized and based
on physician preference. Clinical follow-up occurred every 1
to 3 months after catheter ablation of AF, with adverse
events and deaths evaluated by chart review, telephone
consultations, and review of the National Death Registry of
Taiwan.
The combined endpoint of adverse events included isch-
emic stroke, transient ischemic attack (TIA), peripheral
embolism, pulmonary embolism, and death. Overall, 27
(4.8%) adverse events occurred, including 9 deaths, 9
ischemic strokes, 6 TIAs, 1 peripheral embolus, and 2
pulmonary emboli. Baseline CHADS2 and CHA2DS2-
VASc scores were calculated. The predictive accuracy of
each score, as well as the optimal cutoff values to predict
adverse events was identified using receiver-operator char-
acteristic curves. Univariate analysis demonstrated that older
age, hypertension, congestive heart failure, coronary artery
disease, previous TE event, larger LA diameter, and persis-
tent AF were associated with adverse events. Multivariate
analysis demonstrated that the only independent predictors
of adverse events were the CHADS2 and CHA2DS2-VASc
scores.
Therefore, the authors conclude that the CHADS2 and
CHA2DS2-VASc scores may be useful for predicting ad-
verse events after catheter ablation of AF. A linear relation-
ship between the CHADS2 and CHA2DS2-VASc scores,
nd the rate of adverse events was observed. Using a cutoff
alue of 2 for both the CHADS2 and CHA2DS2-VASc
scores, there was a significant difference in event rates in
patients undergoing catheter ablation of AF with CHADS2
scores2 or2 (15.2% vs. 2.4%), as well as in patients with
HA2DS2-VASc scores2 or2 (11.1% vs. 1.1%). However,
he most striking finding in this study was seen among the
60 patients with a CHADS2 score of 0 or 1. There were 11
(2.4%) adverse events in this group. Among these 460
patients, 98 (21%) had a CHA2DS2-VASc score of 2. The
dverse event rate of the 362 patients with a CHADS2 score of
or 1 and a CHA2DS2-VASc score of2 was 1.1%, whereas
he adverse event rate among of the 98 patients with a
HADS2 score of 0 or 1 and a CHA2DS2-VASc score of2
as 7.1%. These data demonstrate the improved sensitivity of
he CHA2DS2-VASc scoring system.
The authors point out at least 2 important limitations of
this study. First, the use of anticoagulation therapy was not
standardized, and low-risk patients may not have received
oral anticoagulation therapy for the first 3 months after
catheter ablation of AF. Generally, oral anticoagulation
therapy is recommended for at least the first 3 months after
catheter ablation of AF, regardless of the baseline risk of a
TE event. This may explain the relatively high rate of TEevents in this study. Second, this was an observational study
with nonuniform follow-up.
Overall, the authors should be congratulated for their
successful effort in identifying a method to predict which
patients undergoing catheter ablation of AF may be at
increased risk for TE events and death. The CHA2DS2-
VASc score has been incorporated into the European
Society of Cardiology 2010 AF guidelines, but is not
mentioned in the AHA/ACC 2011 update to the 2006 AF
guidelines (1,2,14). Perhaps this is why healthcare providers
in the United States mainly utilize the CHADS2 risk
tratification scoring system to help guide antithrombotic
herapy in patients with AF. For patients with AF and
HADS2 scores 2, oral anticoagulation therapy is clearly
superior to aspirin in prevention of TE events (1,2). How-
ever, for patients with AF and a CHADS2 score of 0 or 1,
he CHA2DS2-VASc score may help to identify the “low
isk” patient at “high risk” for a TE event. The data from
hao et al. (13) may allow us to identify the patient who is
t high risk for a TE event, but has a hanging CHAD.
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